EHA

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, European Hematology Association, Paroxysmal nocturnal hemoglobinuria, Consultant, Pharmacokinetics, Society for Integrative Oncology, Haematopoietic system, Teaching hospital, Congress, Corporation, MD, Royal College of Pathologists, CEST, PNH, EHA, Patient, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.

Key Points: 
  • Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.
  • The presentation abstract (#LB2714) was embargoed by EHA until 16:00 CEST today but now is freely accessible on EHA’s website.
  • Following Dr. Panse’s presentation, Omeros will make available on its website the associated slides.
  • Dr. Griffin’s presentation is scheduled for 18:00-19:00 CEST on Friday, June 9, 2023 and will be available for viewing by registered attendees on the online EHA platform throughout the duration of the congress (June 8-11, 2023).

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

Retrieved on: 
Thursday, June 1, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Abstract, Ruxolitinib, Senior, Myelodysplastic syndrome, Concept, Bone marrow, Drug, Doctor of Philosophy, Quality, Acute myeloid leukemia, MDS, Congress, CAR, AML, MD, Patient, Quality of life, EHA, Science, Tumor microenvironment, Combination, Incidence, Pharmaceutical industry, Dietary supplement, Primary myelofibrosis, Calreticulin

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
  • “The presentation of longer-term follow-up data from our pivotal studies and real-world evidence reinforce the potential of cell therapy across different blood cancers, lines of treatment and settings,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.
  • Other data include efficacy and safety information, healthcare resource use in patients with AML and MDS, and proof-of-concept of magrolimab on calreticulin in myelofibrosis CD34-positive cells.
  • “Our data at EHA demonstrate the growing breadth and promise of our development program across many different blood cancers,” said Carol O’Hear, MD, Vice President, Clinical Development, Gilead Oncology.

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

iOnctura to present research at leading scientific conferences in June 2023

Retrieved on: 
Thursday, June 1, 2023
European Hematology Association, Research, ASCO, Congress, Patrick Schöffski, American Society of Clinical Oncology, CEST, EHA, Annual general meeting, Society, Pharmaceutical industry

GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.

Key Points: 
  • GENEVA and AMSTERDAM, June 1, 2023 /PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023.
  • The iOnctura team will present the Company's research on its first-in-class, non-ATP-competitive, allosteric modulator of PI3Kδ, roginolisib.
  • American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA
    European Hematology Association (EHA) Hybrid Congress, Frankfurt, Germany
    European Association for Cancer Research (EACR) Congress 2023, Torino, Italy
    Presentation Time: 14 June 2023 at 11:00-18:00 CEST.

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

Retrieved on: 
Wednesday, May 31, 2023
European Hematology Association, SYK, TUS, Cell, Acute myeloid leukemia, KIT, Drug resistance, AML, Patient, SAN, EHA, FLT3, TSX, International Congress on Tuberculosis, Phenotype, Venetoclax, Safety, Pharmaceutical industry, Vaccine

The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial.

Key Points: 
  • The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial.
  • Aptose management will highlight additional insights from the completed Phase 1/2 dose escalation clinical trial of tuspetinib and review early trends from the ongoing APTIVATE trial.
  • The slides will be available on Aptose’s website here and the webcast of the presentation will be archived shortly after the conclusion of the event.
  • Strikingly, acquired TUS resistance generated a synthetic lethal vulnerability in which the cells were unusually hypersensitive to venetoclax.

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Tuesday, May 30, 2023
Abstract, Congress, Cancer, AML, SAN, KURA, EHA, Pharmaceutical industry

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

Key Points: 
  • ET on Monday, June 12, 2023 –
    SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.
  • Late-breaking abstract # LB2713, entitled “Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1-mutated AML,” will be presented at the late-breaking oral session from 9:45-11:15 CET on Sunday, June 11, 2023.
  • Late-breaking abstracts are scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023.
  • The event will be webcast live and can be accessed on the Investors section of Kura’s website at www.kuraoncology.com .

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Health, Oncology, Abstract, Abstract (summary), DLBCL, Lymphoma, NHL, B-cell lymphoma, ASCO, Congress, American Society of Clinical Oncology, International Conference on Conceptual Modeling, AbbVie, EHA, Annual general meeting, Society, Conference, Safety, Cryptocurrency, Vaccine

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.
  • Presentations will include data from clinical trials evaluating the efficacy of epcoritamab in combination with standard-of-care therapies for the treatment of various types of B-cell non-Hodgkin lymphoma (NHL), including first-line, high-risk diffuse large B-cell lymphoma (DLBCL), relapsed or refractory large B-cell lymphoma (LBCL), and relapsed or refractory follicular lymphoma (FL).
  • The safety and efficacy of epcoritamab has not been established for these investigational uses.
  • Abstracts accepted for presentation at ASCO include:

Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Pharmaceutical, Health, Oncology, LBA, HER2, Neoplasm, Cancer, Breast, Multimedia, Medicine, Research, NSCLC, Immunotherapy, Carboplatin, Acute myeloid leukemia, ASCO, VEGF, AML, MD, Patient, Daiichi Sankyo, EHA, Dato, ADC, CDT, R, JST, Biliary tract, Pembrolizumab, PARP, Sarah Cannon Research Institute, Fine chemical, Pharmaceutical industry, Medical imaging

Data from DESTINY-PanTumor02 will be featured in an ASCO press briefing.

Key Points: 
  • Data from DESTINY-PanTumor02 will be featured in an ASCO press briefing.
  • “Our data at ASCO and EHA represent another step forward in realizing our vision to create new standards of care for patients with cancer.
  • Executives from Daiichi Sankyo will provide an overview of the ASCO research data and address questions.
  • Highlights of data from Daiichi Sankyo’s DXd ADC portfolio at 2023 ASCO include: